|
|
|
题名
|
作者
|
年代
|
出处
|
被引量
|
| 1 | Phase I and pharmacokineticstudy of ABI- 007,a cremophorfree,protein-stabilized,nanoparticleformulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 2 | Pulmonary artery catheters for adult patients in intensive care显示文摘 | Rajaram SS Desai NK Kalra A | 2013 | Cochrane Database Syst Rev2013，2，00： | 1 |
| 3 | Phase I and pharmaeokinetic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clinical Cancer Res2002，8，： | 1 |
| 4 | Phase Ⅰ and pharmacokinetic study of ABI-007, a Cremophor-free, protein- stabilized, nanoparticle formulation of paclitaxel显示文摘 | IBRAHIM NK DESAI N LEGHA S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 5 | Puhnonary ar- tery catheters for adult patients in intensive care 显示文摘 | Rajaram SS Desai NK Kalra A | 2013 | Cochrane Database Syst Rev2013，，00： | 1 |
| 6 | Phase I and pharmaco- kinetic study of ABI-007, a Cremophor-free proteinstabilized, nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 7 | Phase I and pharmaeo - ki- netic study of ABI - 007, a Cremophor - free, protein - stabilized, nanoparticle formulation of paelitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Cliii Cancer Res2002，8，： | 1 |
| 8 | Effects of a combination of docosahexaenoic acid and 1,4-phenylene bis(methylene) selenocyanate on cyclooxygenase 2,inducible nitric oxide synthase and beta-catenin pathways in colon cancer cells显示文摘 | Narayanan BA Narayanan NK Desai D | 2004 | Carcinogenesis2004，25，12： | 1 |
| 9 | Phase Ⅰ and pharmacokinetic study of ABI-007,a cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 10 | Phase I andpharmacokinetic study of ABI-007,a Cremophor-free,protein-stabilized ,nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | ClinCancer Res2002，8，5： | 1 |
| 11 | Phase I and pharmacokinetic study of ABI-007,a Cremophor-fi'ee,protein-stabilized,nanoparticle formulation ofpaclitaxel显示文摘 | lbrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，05： | 1 |
| 12 | Cellular localization and functional significance of CYP3A4 in the human epileptic brain显示文摘 | GHOSH C MARCHI N DESAI NK et d | 2011 | Epilepsia2011，52，3： | 1 |
| 13 | Phase I and pharma- cokinetic study of ABI-007, a Cremophor-free, protein - stabilized, nanoparticle formulation of Paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 14 | Phase I and pharmacokinetic study of ABI-007, a Cremophor free, protein-stabilized, nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 15 | Magnetic resonanceimaging of the brain in glutaric acidemia type I: a review of theliterature and a report of four new cases with attention to thebasal ganglia and imaging technique显示文摘 | Desai NK Runge VM Crisp DE | 2003 | Invest Radiol2003，38，： | 1 |
| 16 | Phase I and pharmacokinetic study of ABI-007, a cremophor-free proteinstabilized, nanoparticle for- mulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 17 | Phase Ⅰ and pharmacokinetic study of ABI 007,a Cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，： | 1 |
| 18 | Phase I and pharmacoki- netic study of ABI-O07, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 19 | Phase I and pharmacokinetic study of ABI-007,a cremophor-free,protein-stabilized,nanoparticle formulation of paclitaxel显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
| 20 | Phase I and pharmacokinetic study of ABI-007, a Cremophor-free, protein-stabilized, nanoparticle formulation of paclitaxel 显示文摘 | Ibrahim NK Desai N Legha S | 2002 | Clin Cancer Res2002，8，5： | 1 |
您所在的机构暂未开通此部分的功能，请联系管理员